Recombinant Desulphatohirudin (CGP 39393) Anticoagulant and Antithrombotic Properties In Vivo

Summary

The effects of the newly available biotechnology product, recombinant desulphatohirudin (CGP 39393) have been investigated in rats. This highly potent and selective thrombin inhibitor exhibited marked anticoagulant properties with controllable titration of anticoagulant effect, as measured by activated partial thromboplastin time (APTT), up to nearly four times control values. Furthermore, CGP 39393 exhibited impressive antithrombotic activity in vivo. In an arteriovenous shunt model of thrombus formation on a cotton-thread, the compound was capable of complete inhibition of thrombus development (ED₅₀ = 0.3 mg/kg i.v. and 1.0 mg/kg s.c.). Venous stasis thrombosis was also highly susceptible to inhibition by CGP 39393 (ED₅₀ = 0.01 mg/kg i.v. and 0.45 mg/kg s.c.). Comparison of the anticoagulant and antithrombotic activities of the compound shows that potent antithrombotic effects (83-97% inhibition in the rat shunt model) are achieved within the generally acceptable range of anticoagulation. These results suggest a clear potential for this new agent in the clinical treatment of thrombotic disease.

Key words

Recombinant desulphatohirudin - CGP 39393 - Hirudin - Man - Thrombin inhibitor - Anticoagulant - Antithrombotic

• References

• 1 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches. Biomed Biochem Acta 1985; 44: 1007-1013
• 2 Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 69: 924-932
• 3 Markwardt F, Nowak G, Stürzebecher J, Grießbach V, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemostas 1984; 52: 160-163
• 4 Markwardt F, Hauptmann J, Nowak G, Kleßen Ch. Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemostas 1982; 47: 226-229
• 5 Meyhack B, Heim J, Rink H, Zimmerman W, Märki W. Desulphatohirudin, a specific thrombin inhibitor: expression and secretion in yeast. Thromb Haemostas (Brussels) 1987; Suppl 8: 33
• 6 Grossenbacher H, Auden J, Bill K, Liersch M, Märki W. Isolation and characterisation of recombinant desulphatohirudin from yeast: a highly selective thrombin inhibitor. Thromb Haemostas (Brussels) 1987; Suppl 8: 34
• 7 Smith JR, White AM. Fibrin, red cell and platelet interactions in an experimental model of thrombosis. Br J Pharmacol 1982; 77: 29-38
• 8 Hladovec J. A sensitive model of venous thrombosis in rats. Thromb Res 1986; 43: 539-544
• 9 Perry MO. Anticoagulation: a surgical perspective. Am J Surg 1988; 155: 268-76
• 10 Hemker HC, Béguin S. Thrombosis and thrombin. In: The Biology and Pathology of Platelet-Vessel Wall Interactions. Jolies G, Legrand Y, Nurden A. (eds) Academie Press; London: 1986. pp 219-226